Skip to main content

Table 2 Associations between healthy lifestyle index score change and lifestyle-related, alcohol-related, tobacco-related, obesity-related, reproductive-related, breast, and colorectal cancer incidence in the Norwegian Women and Cancer Study (n = 66,233), imputed analysis

From: Overall lifestyle changes in adulthood are associated with cancer incidence in the Norwegian Women and Cancer Study (NOWAC) – a prospective cohort study

  

Lifestyle-related cancer incidencea

Alcohol-related cancer incidencea

Tobacco-related cancer incidence

Obesity-related cancer incidencea

Reproductive-related cancer incidencea

Breast cancer incidencea

Colorectal cancer incidence

Cases

 

6354

3512

2931

4788

3385

2384

839

Continuous HLI score change

1-SD (2.6 HLI points) increase

0.93(0.90–0.96)

0.96(0.91–0.99)

0.92(0.88–0.96)

0.94(0.91–0.98)

0.90(0.84–0.98)

0.96(0.91–1.01)

0.98(0.90–1.07)

Categorical HLI score change

 <  = -3

1.16(1.05–1.27)

1.06(0.94–1.20)

1.27(1.10–1.45)

1.10(0.99–1.22)

1.21(0.96–1.54)

1.01(0.86–1.18)

1.23(0.94–1.61)

-2

1.10(0.99–1.23)

1.10(0.96–1.26)

1.13(0.97–1.31)

1.09(0.97–1.22)

1.14(0.88–1.48)

1.09(0.92–1.29)

1.07(0.78–1.44)

-1

1.03(0.93–1.13)

1.02(0.90–1.15)

1.08(0.94–1.25)

1.00(0.90–1.11)

1.04(0.81–1.33)

0.99(0.85–1.16)

1.10(0.84–1.45)

0

       

1

0.99(0.89–1.09)

0.97(0.85–1.10)

1.06(0.92–1.23)

0.97(0.87–1.08)

0.93(0.72–1.20)

0.93(0.79–1.05)

1.09(0.82–1.44)

2

0.96(0.86–1.07)

0.98(0.85–1.12)

1.02(0.87–1.18)

0.96(0.86–1.08)

0.88(0.66–1.17)

0.95(0.80–1.13)

1.10(0.81–1.49)

 >  = 3

0.93(0.84–1.03)

0.92–0.81–1.05)

0.98(0.85–1.14)

0.92(0.82–1.03)

1.00(0.78–1.29)

0.89(0.75–1.05)

1.13(0.85–1.50)

HLI score change excluding one factorb

1-SD increase

       

Excluding physical activity

2.0

0.95(0.93–0.98)

0.97(0.93–1.00)

0.94(0.91–0.98)

0.96(0.93–0.99)

0.95(0.88–1.02)

0.97(0.93–1.02)

0.98(0.90–1.06)

Excluding BMI

2.4

0.92(0.89–0.95)

0.95(0.91–0.99)

0.87(0.83–0.91)

0.96(0.93–0.99)

0.98(0.90–1.06)

0.96(0.91–1.01)

0.97(0.88–1.06)

Excluding smoking

2.5

0.95(0.92–0.98)

0.96(0.92–1.00)

0.98(0.94–1.03)

0.94(0.91–0.97)

0.87(0.81–0.94)

0.95(0.91–1.00)

1.00(0.92–1.09)

Excluding alcohol

2.5

0.93(0.90–0.96)

0.97(0.93–1.01)

0.92(0.88–0.96)

0.95(0.92–0.98)

0.89(0.82–0.96)

0.97(0.93–1.02)

0.99(0.91–1.08)

Excluding diet

2.0

0.93(0.90–0.96)

0.96(0.92–1.00)

0.93(0.89–0.97)

0.94(0.91–0.98)

0.90(0.84–0.97)

0.95(0.91–1.00)

0.98(0.90–1.07)

Single HLI factorsc

1-unit increase (score 0–4)

       

Physical activity score change

 

0.96(0.94–0.98)

0.98(0.95–1.01)

0.97(0.93–1.00)

0.98(0.95–1.00)

0.94(0.89–0.99)

0.97(0.94–1.01)

1.01(0.95–1.08)

BMI score change

 

0.98(0.95–1.02)

0.99(0.95–1.03)

1.04(0.99–1.09)

0.96(0.92–0.99)

0.86(0.79–0.94)

0.97(0.92–1.03)

1.03(0.93–1.13)

Smoking score change

 

0.98(0.93–1.03)

1.02(0.95–1.09)

0.94(0.88–1.00)

1.02(0.96–1.07)

1.08(0.95–1.24)

1.02(0.94–1.11)

0.97(0.84–1.12)

Alcohol score change

 

0.98(0.95–1.02)

0.94(0.89–0.99)

1.00(0.94–1.06)

0.97(0.93–1.02)

1.06(0.96–1.18)

0.94(0.88–1.00)

0.97(0.86–1.08)

Diet score change

 

0.99(0.97–1.01)

0.99(0.97–1.02)

0.99(0.97–1.02)

1.00(0.98–1.02)

1.00(0.95–1.05)

1.00(0.96–1.03)

1.00(0.95–1.06)

  1. All models were adjusted for education (years), height (centimetres), HLI score at Q1 (continuous), and calendar year at Q2 (continuous)
  2. aModels additionally adjusted for age at menarche (years), menopausal status (premenopausal/postmenopausal), breastfeeding (cumulative months 0, <  = 12, > 12), hormone replacement therapy use (never/former/current), oral contraceptive use (never/ever), parity (0, 1–2, > 2), and history of breast cancer in a first degree relative (yes/no)
  3. bBaseline HLI score was adjusted by separately adjusting for HLI score at Q1 excluding the factor in question and the individual factor score at Q1
  4. cMutually adjusted for all single factor HLI score changes and single factor HLI scores at Q1
  5. Alcohol-related cancers including sites: upper aerodigestive [C01-C10], pharynx [C11-C14], esophagus [C15], colorectum [C18-C20], liver [C22-C24], larynx [C32], breast [C50],
  6. Tobacco-related cancers including sites: upper aerodigestive [C01-C10], pharynx [C11-C14], esophagus [C15], stomach [C16], colorectum [C18-C20], liver [C22-C24], pancreas [C25], accessory sinus [C31], larynx [C32], trachea [C33], lung [C34], breast [C50], cervix [C53], ovarian [C56], kidney [C64-C66], bladder [C67], acute myeloid leukemia [C92]
  7. Obesity-related cancers including sites: esophagus [C15], stomach [C16], colorectum [C18-C20], liver [C22-C24], pancreas [C25], breast [C50], uterine [C54-C55], ovarian [C56], kidney [C64-C66], thyroid [C73], multiple myeloma [C90],
  8. Reproductive-related cancers including sites: vulva [C51] vagina [C52], cervix [C53], uterine [C54-C55], ovarian [C56], other female genital organs [C57-C58]